AMAvanthi Moodley-Reddy

Avanthi Moodley-Reddy

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Avanthi Moodley-Reddy has a total of 7 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Computational Analysis, In silico Functional Annotation, and Expression of Recombinant PE_PGRS Protein Biomarkers Found in Mycobacterium tuberculosis

    by Avanthi Moodley-Reddy, Thamsanqa Emmanuel Chiliza, Ofentse Jacob Pooe

    Background: Over the years, there have been many advances made within the treatment and diagnosis of Mycobacterium Tuberculosis (Mtb). In recent times, the rise of drug resistance has led to higher mortality rates, specifically in poorer countries. There is an urgent need for novel treatment regimens to work against Mtb. Previous studies have identified a gene family within Mtb, known as PE_PGRS proteins, which has shown potential as a drug target. Functional annotations can assist with identifying the role these proteins may play within Mtb. Methods: Previous studies indicated PE_PGRS to have potential for further research. The protein biomarkers that showed the most promise were identified as PE_PGRS17, PE_PGRS31, PE_PGRS50, and PEPGRS54. The sequences of these proteins were searched on the Mycobrowser software. Results were designed by entering these sequences into various computational algorithms. PE_PGRS17 showed characteristics of a potential vaccine candidate. Considering this result, expression profiling and purification were conducted on the recombinant PE_PGRS17 Mtb protein biomarker. Results and Discussion: The results were calculated using various online software algorithms. Many characteristics were predicted to understand the stability, localization, and function of these proteins. All the proteins have been estimated to produce an immune response or be involved in the process of immunity. The recombinantPE_PGRS17 protein was chosen to be optimally expressed and purified using E.coli as a host cell. These findings specifically on PE_PGRS17, can be expanded in future scientific studies. Conclusion: The predicted structures, protein-protein interaction, and antigenic properties of the proteins estimate whether a protein can be used for further studies, specifically as drug/vaccine targets. Ultimately, PE_PGRS17 is seen as the most stable according to its predicted structure, which holds promise as a key factor in future tuberculosis studies.


  • Open Access

    Computational Analysis, in silico Functional Annotation and Expression of Recombinant mycobacterium, PE_PGRS Protein Biomarkers

    by Avanthi Moodley-Reddy, Thamsanqa Emmanuel Chiliza, Ofentse Jacob Pooe

    Background: Over the years, there have been many advances made within the treatment and diagnosis of Mycobacterium Tuberculosis (Mtb). In recent times, the rise of drug resistance has led to higher mortality rates specifically in poorer countries. There is an urgent need for novel treatment regimens to work against Mtb. A gene family, found in Mtb, PE_PGRS proteins shows potential as a drug target in its life cycle; to prevent the activation of latent Mtb to active Mtb. In silico functional annotations of these proteins are cost-effective and avoid wasting effort on a protein with no potential. Method: Previous studies indicated that the PE_PGRS showed potential for further research. The protein biomarkers which showed the most promise was identified as PE_PGRS17, PE_PGRS31, PE_PGRS50 and PEPGRS54. The sequences of these proteins were searched on the Mycobrowser software. Results were designed by entering these sequences into various computational algorithms. PE_PGRS17 showed characteristics of a potential vaccine candidate. Considering this result, expression profiling and purification was conducted on the recombinant PE_PGRS17 Mtb protein biomarker. Results and Discussion: The results were calculated using various online software algorithms. Many characterizations and other aspects were predicted to understand the stability, localization, and function of these proteins. All the proteins are estimated to produce an immune response or be involved in the process of immunity. The expression condition of the recombinant PE_PGRS17 was optimised, and purification strategy achieved using E.coli as a host cell. These findings make these proteins, specifically PE_PGRS17, popular for further scientific study. Conclusion: The predicted structures, protein-protein interaction and antigenic properties of the proteins estimate whether the protein can be used for further studies specifically as drug/vaccine targets. Ultimately PE_PGRS17 is seen as the most stable according to its structure and it holds more promise as a key factor to tuberculosis studies.

  • Reverse vaccinology approach to design a multi-epitope vaccine construct based on the Mycobacterium tuberculosis biomarker PE_PGRS17

    by Avanthi Moodley, Abiodun Fatoba, Moses Okpeku, Thamsanqa Emmanuel Chiliza, Mthokozisi Blessing Cedric Simelane, Ofentse Jacob Pooe

    Mycobacterium tuberculosis (Mtb) is responsible for high mortality rates in many low- and middle-income countries. This infectious disease remains accountable for around 1.4 million deaths yearly. Finding effective control measures against Mtb has become imperative. Vaccination has been regarded as the safe and lasting control measure to curtail the impact of Mtb. This study used the Mtb protein biomarker PE_PGRS17 to design a multi-epitope vaccine. A previous study predicted a strong antigenic property of PE_PGRS17. Immunogenic properties such as antigenicity, toxicity, and allergenicity were predicted for the PE_PGRS17 biomarker, specific B- and T-cell epitope sequences, and the final multiple epitope vaccine (MEV) construct. Algorithmic tools predicted the T- and B-cell epitopes and those that met the immunogenic properties were selected to construct the MEV candidate for predicted vaccine development. The epitopes were joined via linkers and an adjuvant was attached to the terminals of the entire vaccine construct. Immunogenic properties, and physicochemical and structural predictions gave insight into the MEV construct. The assembled vaccine candidate was docked with a receptor and validated using web-based tools. An immune simulation was performed to imitate the immune response after exposure to a dosed administrated predicted MEV subunit. An in silico cloning and codon optimisation gave insight into optimal expression conditions regarding the MEV candidate. In conclusion, the generated MEV construct may potentially emit both cellular and humoral responses which are vital in the development of a peptide-based vaccine against Mtb; nonetheless, further experimental validation is still required.